Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: A multicenter, randomized, controlled clinical trial

Mirco Ros, Rosaria Casciaro, Francesca Lucca, Patrizia Troiani, Elena Salonini, Federica Favilli, Serena Quattrucci, Daniel Sher, Baroukh Maurice Assael

Research output: Contribution to journalArticle

Abstract

Trial Design and Methods: Between December 2009 and July 2011, four cystic fibrosis (CF) centers in Italy participated in a randomized, double-blind, controlled clinical trial to test whether 7% hypertonic saline (HS) administered together with 0.1% hyaluronic acid (HA) was better tolerated by patients who previously did not tolerate HS well on its own. Participants were CF patients at least 8 years old, in clinically stable conditions, with forced expiratory volume in 1sec (FEV1) at least 50% predicted. Forty patients were recruited and randomized to receive either HS or HS plus HA (5mL to be inhaled over 15min, twice daily for 28 days). Primary endpoints were cough, throat irritation, salty taste, and overall acceptability, as assessed by each patient on a semiquantitative scale on a diary card. Secondary endpoint was FEV 1 change at the end of treatment. Patients were randomized into randomly permuted blocks. The first and last doses were administered in hospital. In between, patients were treated at home. Patients, all caregivers, and the statistician who conducted the analysis (different from the one who generated the random list) were blinded to group assignment. Results: Severity of cough, throat irritation, and saltiness were more severe in patients treated with HS alone, both after the first inhalation and over the entire treatment period. Overall pleasantness was rated higher by patients treated with the combination product. All differences were highly significant. There were no changes in FEV1 between the first and last administrations. Five patients did not complete the study. Four patients (two from each group) withdrew because of cough or throat irritation. One more patient from the HS group withdrew because of a respiratory exacerbation at week 3. Conclusions: HS is currently a cornerstone in the treatment of CF patients. The addition of HA to HS reduces the prevalence and severity of cough, throat irritation, and saltiness and may improve compliance in patients who previously did not tolerate HS well on its own. Longer-term studies could further assess the benefit of chronic treatment.

Original languageEnglish
Pages (from-to)133-137
Number of pages5
JournalJournal of Aerosol Medicine and Pulmonary Drug Delivery
Volume27
Issue number2
DOIs
Publication statusPublished - Apr 1 2014

Fingerprint

Hyaluronic Acid
Cystic Fibrosis
Randomized Controlled Trials
Pharynx
Cough
Therapeutics
Forced Expiratory Volume
Controlled Clinical Trials
Patient Compliance
Inhalation
Italy
Caregivers

Keywords

  • Clinical trial
  • cystic fibrosis
  • Hyaluronan
  • Hypertonic saline
  • Inhaled therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)
  • Pharmaceutical Science
  • Medicine(all)

Cite this

Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients : A multicenter, randomized, controlled clinical trial. / Ros, Mirco; Casciaro, Rosaria; Lucca, Francesca; Troiani, Patrizia; Salonini, Elena; Favilli, Federica; Quattrucci, Serena; Sher, Daniel; Assael, Baroukh Maurice.

In: Journal of Aerosol Medicine and Pulmonary Drug Delivery, Vol. 27, No. 2, 01.04.2014, p. 133-137.

Research output: Contribution to journalArticle

Ros, Mirco ; Casciaro, Rosaria ; Lucca, Francesca ; Troiani, Patrizia ; Salonini, Elena ; Favilli, Federica ; Quattrucci, Serena ; Sher, Daniel ; Assael, Baroukh Maurice. / Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients : A multicenter, randomized, controlled clinical trial. In: Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2014 ; Vol. 27, No. 2. pp. 133-137.
@article{818854cdf2774f66ae676fc287184064,
title = "Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: A multicenter, randomized, controlled clinical trial",
abstract = "Trial Design and Methods: Between December 2009 and July 2011, four cystic fibrosis (CF) centers in Italy participated in a randomized, double-blind, controlled clinical trial to test whether 7{\%} hypertonic saline (HS) administered together with 0.1{\%} hyaluronic acid (HA) was better tolerated by patients who previously did not tolerate HS well on its own. Participants were CF patients at least 8 years old, in clinically stable conditions, with forced expiratory volume in 1sec (FEV1) at least 50{\%} predicted. Forty patients were recruited and randomized to receive either HS or HS plus HA (5mL to be inhaled over 15min, twice daily for 28 days). Primary endpoints were cough, throat irritation, salty taste, and overall acceptability, as assessed by each patient on a semiquantitative scale on a diary card. Secondary endpoint was FEV 1 change at the end of treatment. Patients were randomized into randomly permuted blocks. The first and last doses were administered in hospital. In between, patients were treated at home. Patients, all caregivers, and the statistician who conducted the analysis (different from the one who generated the random list) were blinded to group assignment. Results: Severity of cough, throat irritation, and saltiness were more severe in patients treated with HS alone, both after the first inhalation and over the entire treatment period. Overall pleasantness was rated higher by patients treated with the combination product. All differences were highly significant. There were no changes in FEV1 between the first and last administrations. Five patients did not complete the study. Four patients (two from each group) withdrew because of cough or throat irritation. One more patient from the HS group withdrew because of a respiratory exacerbation at week 3. Conclusions: HS is currently a cornerstone in the treatment of CF patients. The addition of HA to HS reduces the prevalence and severity of cough, throat irritation, and saltiness and may improve compliance in patients who previously did not tolerate HS well on its own. Longer-term studies could further assess the benefit of chronic treatment.",
keywords = "Clinical trial, cystic fibrosis, Hyaluronan, Hypertonic saline, Inhaled therapy",
author = "Mirco Ros and Rosaria Casciaro and Francesca Lucca and Patrizia Troiani and Elena Salonini and Federica Favilli and Serena Quattrucci and Daniel Sher and Assael, {Baroukh Maurice}",
year = "2014",
month = "4",
day = "1",
doi = "10.1089/jamp.2012.1034",
language = "English",
volume = "27",
pages = "133--137",
journal = "Journal of Aerosol Medicine and Pulmonary Drug Delivery",
issn = "1941-2711",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients

T2 - A multicenter, randomized, controlled clinical trial

AU - Ros, Mirco

AU - Casciaro, Rosaria

AU - Lucca, Francesca

AU - Troiani, Patrizia

AU - Salonini, Elena

AU - Favilli, Federica

AU - Quattrucci, Serena

AU - Sher, Daniel

AU - Assael, Baroukh Maurice

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Trial Design and Methods: Between December 2009 and July 2011, four cystic fibrosis (CF) centers in Italy participated in a randomized, double-blind, controlled clinical trial to test whether 7% hypertonic saline (HS) administered together with 0.1% hyaluronic acid (HA) was better tolerated by patients who previously did not tolerate HS well on its own. Participants were CF patients at least 8 years old, in clinically stable conditions, with forced expiratory volume in 1sec (FEV1) at least 50% predicted. Forty patients were recruited and randomized to receive either HS or HS plus HA (5mL to be inhaled over 15min, twice daily for 28 days). Primary endpoints were cough, throat irritation, salty taste, and overall acceptability, as assessed by each patient on a semiquantitative scale on a diary card. Secondary endpoint was FEV 1 change at the end of treatment. Patients were randomized into randomly permuted blocks. The first and last doses were administered in hospital. In between, patients were treated at home. Patients, all caregivers, and the statistician who conducted the analysis (different from the one who generated the random list) were blinded to group assignment. Results: Severity of cough, throat irritation, and saltiness were more severe in patients treated with HS alone, both after the first inhalation and over the entire treatment period. Overall pleasantness was rated higher by patients treated with the combination product. All differences were highly significant. There were no changes in FEV1 between the first and last administrations. Five patients did not complete the study. Four patients (two from each group) withdrew because of cough or throat irritation. One more patient from the HS group withdrew because of a respiratory exacerbation at week 3. Conclusions: HS is currently a cornerstone in the treatment of CF patients. The addition of HA to HS reduces the prevalence and severity of cough, throat irritation, and saltiness and may improve compliance in patients who previously did not tolerate HS well on its own. Longer-term studies could further assess the benefit of chronic treatment.

AB - Trial Design and Methods: Between December 2009 and July 2011, four cystic fibrosis (CF) centers in Italy participated in a randomized, double-blind, controlled clinical trial to test whether 7% hypertonic saline (HS) administered together with 0.1% hyaluronic acid (HA) was better tolerated by patients who previously did not tolerate HS well on its own. Participants were CF patients at least 8 years old, in clinically stable conditions, with forced expiratory volume in 1sec (FEV1) at least 50% predicted. Forty patients were recruited and randomized to receive either HS or HS plus HA (5mL to be inhaled over 15min, twice daily for 28 days). Primary endpoints were cough, throat irritation, salty taste, and overall acceptability, as assessed by each patient on a semiquantitative scale on a diary card. Secondary endpoint was FEV 1 change at the end of treatment. Patients were randomized into randomly permuted blocks. The first and last doses were administered in hospital. In between, patients were treated at home. Patients, all caregivers, and the statistician who conducted the analysis (different from the one who generated the random list) were blinded to group assignment. Results: Severity of cough, throat irritation, and saltiness were more severe in patients treated with HS alone, both after the first inhalation and over the entire treatment period. Overall pleasantness was rated higher by patients treated with the combination product. All differences were highly significant. There were no changes in FEV1 between the first and last administrations. Five patients did not complete the study. Four patients (two from each group) withdrew because of cough or throat irritation. One more patient from the HS group withdrew because of a respiratory exacerbation at week 3. Conclusions: HS is currently a cornerstone in the treatment of CF patients. The addition of HA to HS reduces the prevalence and severity of cough, throat irritation, and saltiness and may improve compliance in patients who previously did not tolerate HS well on its own. Longer-term studies could further assess the benefit of chronic treatment.

KW - Clinical trial

KW - cystic fibrosis

KW - Hyaluronan

KW - Hypertonic saline

KW - Inhaled therapy

UR - http://www.scopus.com/inward/record.url?scp=84897059697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897059697&partnerID=8YFLogxK

U2 - 10.1089/jamp.2012.1034

DO - 10.1089/jamp.2012.1034

M3 - Article

C2 - 23745525

AN - SCOPUS:84897059697

VL - 27

SP - 133

EP - 137

JO - Journal of Aerosol Medicine and Pulmonary Drug Delivery

JF - Journal of Aerosol Medicine and Pulmonary Drug Delivery

SN - 1941-2711

IS - 2

ER -